Quinoline Formulation Stability and Solubility via Excipient Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of substituted quinolines, such as Compound A, face challenges with low solubility, stability issues, and cohesive properties, leading to problems in tableting and uniformity, as well as degradation over time, especially under moist conditions and light exposure.
Innovation Solution
A pharmaceutical formulation comprising a compound of Formula I or II, along with a filler, disintegrant, binder, and lubricant, specifically optimized in terms of weight percentages and excipients like mannitol, sodium starch glycolate, hydroxypropyl cellulose, and glyceryl behenate, to improve solubility, stability, and flowability, and prepared through a method involving sieving, mixing, and drying to create a stable and effective dosage form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted quinolines are used as pharmaceutical formulations, then therapeutic efficacy against kinase-mediated diseases is achieved, but solubility is low and stability issues occur
Solution Approach 1:
The patent applies parameter changes by optimizing the weight percentage composition of excipients (filler: 80-90%, disintegrant: 2-6%, binder: 0.25-0.75%, lubricant: 1.5-4%) to improve solubility and stability while maintaining therapeutic efficacy. This quantitative adjustment of formulation parameters resolves the contradiction between efficacy and solubility/stability.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation by combining substituted quinoline compounds with multiple excipients (fillers like mannitol, disintegrants like sodium starch glycolate, binders like hydroxypropyl cellulose, and lubricants like glyceryl behenate). This composite approach enhances solubility and stability while preserving the therapeutic action of the active compound.
2Manufacturing precision
If substituted quinolines are formulated for pharmaceutical use, then dosage uniformity is required, but cohesive properties cause tableting problems
Solution Approach 1:
The patent introduces excipients as intermediary substances that mediate between the cohesive active compound and the tableting process. Specifically, lubricants (1.5-4% w/w) reduce inter-particle friction and prevent sticking, while binders (0.25-0.75% w/w) provide appropriate adhesion. These intermediaries enable uniform dosing without compromising the tableting process.
Solution Approach 2:
The patent applies local quality by assigning specific functions to different excipients in the formulation. Each component (filler, disintegrant, binder, lubricant) is optimized for its specific role: fillers provide bulk and flow, disintegrants enable tablet breakup, binders provide cohesion, and lubricants reduce friction. This functional differentiation resolves the contradiction between dosage uniformity and ease of manufacture.
3Duration of action of stationary object
If substituted quinolines are stored over time, then shelf life is extended, but degradation occurs under moist conditions and light exposure
Solution Approach 1:
The patent creates an inert microenvironment within the formulation by selecting excipients that are chemically inert and resistant to moisture and light. Fillers like mannitol and binders like hydroxypropyl cellulose provide a stable matrix that protects the active compound from degradation. This inert environment extends shelf life by preventing harmful interactions with moisture and light.
Solution Approach 2:
The patent applies beforehand cushioning by incorporating stabilizing excipients that preemptively protect the active compound from degradation. The formulation design includes components that absorb moisture, resist oxidation, and protect against light exposure before degradation can occur. This preventive approach extends shelf life by cushioning the active compound against environmental stressors.
Data Source
AI summary
The present disclosure is directed to formulations of novel quinolines and their pharmaceutically acceptable salts, which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this disclosure have a general Formula Iwherein R10 to R14 and X are defined herein.